SUBCUTANEOUS DARATUMUMAB + BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE (VCD) IN PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN (AL) AMYLOIDOSIS: UPDATED RESULTS FROM THE PHASE 3 ANDROMEDA STUDY
a Clínica CEHON, Rede D'Or Oncologia, Salvador, BA, Brazil
b Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
c Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, United States
d Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Read
2874
Timeswas read the article
987
Total PDF
1887
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 7 | 2 | 1 | 3 |
| 2025 6 | 60 | 15 | 75 |
| 2025 5 | 70 | 16 | 86 |
| 2025 4 | 43 | 13 | 56 |
| 2025 3 | 69 | 16 | 85 |
| 2025 2 | 47 | 24 | 71 |
| 2025 1 | 62 | 30 | 92 |
| 2024 12 | 34 | 13 | 47 |
| 2024 11 | 59 | 26 | 85 |
| 2024 10 | 56 | 35 | 91 |
| 2024 9 | 65 | 15 | 80 |
| 2024 8 | 54 | 25 | 79 |
| 2024 7 | 47 | 26 | 73 |
| 2024 6 | 49 | 25 | 74 |
| 2024 5 | 53 | 39 | 92 |
| 2024 4 | 51 | 29 | 80 |
| 2024 3 | 54 | 28 | 82 |
| 2024 2 | 43 | 25 | 68 |
| 2024 1 | 36 | 16 | 52 |
| 2023 12 | 48 | 27 | 75 |
| 2023 11 | 66 | 27 | 93 |
| 2023 10 | 55 | 24 | 79 |
| 2023 9 | 71 | 32 | 103 |
| 2023 8 | 64 | 27 | 91 |
| 2023 7 | 41 | 24 | 65 |
| 2023 6 | 68 | 19 | 87 |
| 2023 5 | 61 | 18 | 79 |
| 2023 4 | 46 | 10 | 56 |
| 2023 3 | 33 | 18 | 51 |
| 2023 2 | 43 | 19 | 62 |
| 2023 1 | 23 | 13 | 36 |
| 2022 12 | 25 | 13 | 38 |
| 2022 11 | 32 | 27 | 59 |
| 2022 10 | 37 | 23 | 60 |
| 2022 9 | 43 | 26 | 69 |
| 2022 8 | 24 | 20 | 44 |
| 2022 7 | 18 | 30 | 48 |
| 2022 6 | 23 | 22 | 45 |
| 2022 5 | 21 | 25 | 46 |
| 2022 4 | 16 | 17 | 33 |
| 2022 3 | 18 | 15 | 33 |
| 2022 2 | 12 | 19 | 31 |
| 2022 1 | 12 | 18 | 30 |
| 2021 12 | 16 | 18 | 34 |
| 2021 11 | 12 | 23 | 35 |
| 2021 10 | 5 | 16 | 21 |
Show all
